Modeling disease progression with longitudinal markers

Journal of the American Statistical Association

Volumn 103, Issue 481, 2008, Pages 259-270

  Inoue, Lurdes Y T ^a   Etzioni, Ruth ^b   Morrell, Christopher ^c,d   Müller, Peter ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c LOYOLA UNIVERSITY MARYLAND   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

Disease progression; Latent variables; Longitudinal response; Markov chain Monte Carlo methods; Natural history model; Prostate specific antigen

Indexed keywords

EID: 42349097208     PISSN: 01621459     EISSN: None     Source Type: Journal    
DOI: 10.1198/016214507000000356     Document Type: Article

References (44)

1. Bartoszynski, R., Edler, L., Hanin, L., Kopp-Schneider, A., Pavlova, L., Tsodikov, A., Zorin, A., and Yakovlev, A. Y. (2001), "Modeling Cancer Detection: Tumor Size as a Source of Information on Unobservable Stages of Carcinogenesis," Mathematical Biosciences, 171, 113-142.
2. Brookmeyer, R. (1991), "Reconstruction and Future Trends of the AIDS Epidemic in the United States," Science, 253, 37-42.
3. Brookmeyer, R., and Goedert, J. J. (1989), "Censoring in an Epidemic With an Application to Hemophilia-Associated AIDS," Biometrics, 45, 325-335.
4. Carter, H. B., Epstein, J. I., Chan, D. W., Fozard, J. L., and Pearson, J. D. (1997), "Recommended Prostate-Specific Antigen Testing Intervals for the Detection of Curable Prostate Cancer," Journal of the American Medical Association, 277, 1456-1460.
5. Craig, B. A., Fryback, D. G., Klein, R., and Klein, B. E. K. (1999), "A Bayesian Approach to Modelling the Natural History of a Chronic Condition From Observations With Intervention," Statistics in Medicine, 18, 1355-1371.
6. Crawford, E. D., Leewansangtong, S., Goktas, S., Houlthaus, K., and Baier, M. (1999), "Efficiency of Prostate-Specific Antigen and Digital Rectal Examination in Screening, Using 4.0 ng/ml and Age-Specific Reference Range as a Cutoff for Abnormal Values," The Prostate, 38, 296-302.
7. Day, N. E., and Walter, S. D. (1984), "Simplified Models of Screening for Chronic Disease: Estimation Procedures From Mass Screening Programmes," Biometrics, 40, 1-13.
8. DeGruttola, V., and Lagakos, S. W. (1989), "Analysis of Doubly-Censored Survival Data, With Application to AIDS," Biometrics, 45, 1-11.
9. DeGruttola, V., Lange, N., and Dafni, U. (1991), "Modeling the Progression of HIV Infection," Journal of the American Statistical Association, 86, 569-577.
10. Etzioni, R., Penson, D. F., Legler, J. M., di Tommaso, D., Boer, R., Gann, P. H., and Feuer, E. J. (2002), "Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends," Journal of the National Cancer Institute, 94, 981 -990.
11. Foulkes, A. S., and DeGruttola, V. (2003), "Characterizing the Progression of Viral Mutations Over Time," Journal of the American Statistical Association, 98, 859-867.
12. Gann, P. H., Hennekens, C. H., and Stampfer, M. J. (1995), "A Prospective Evaluation of Plasma Prostate-Specific Antigen for Detection of Prostatic Cancer," Journal of the American Medical Association, 273, 289-294.
13. Gelfand, A. E., Dey, D. K., and Chang, H. (1992), "Model Determination Using Predictive Distributions With Implementation via Sampling-Based Methods" (with discussion), in Bayesian Statistics 4, eds. J. M. Bernardo, J. O. Berger, A. P. Dawid, and A. F. M. Smith, New York: Oxford University Press, pp. 147-167.
14. Gelfand, A. E., and Smith, A. F. M. (1990), "Sampling-Based Approaches to Calculating Marginal Densities," Journal of the American Statistical Association, 85, 398-409.
15. Geman, S., and Geman, D. (1984), "Stochastic Relaxation, Gibbs Distributions, and the Bayesian Restoration to Images," IEEE Transactions on Pattern Analysis and Machine Intelligence, 6, 721-741.
16. Geweke, J. (1992), "Evaluating the Accuracy of Sampling-Based Approahces to Calculating Posterior Moments," in Bayesian Statistics 4, eds. J. M. Bernardo, J. O. Berger, A. P. Dawid, and A. F. M. Smith, New York: Oxford University Press, pp. 169-194.
17. Inoue, L. Y. T., Etzioni, R., Slate, E. H., Morrell, C., and Penson, D. F. (2004), "Combining Longitudinal Studies of PSA," Biostatistics, 5, 483-500.
18. Jackson, C. H., and Sharples, L. D. (2002), "Hidden Markov Models for the Onset and Progression of Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients," Statistics in Medicine, 21, 113-128.
19. Jackson, C. H., Sharpies, L. D., Thompson, S. G., Duffy, S. W., and Couto, E. (2003), "Multistate Markov Models for Disease Progression With Classification Error," The Statistician, 52, 193-209.
20. Kass, R. E., and Raftery, A. E. (1995), "Bayes Factors," Journal of the American Statistical Association, 90, 773-795.
21. Kay, R. (1986), "A Markov Model for Analysing Cancer Markers and Disease States in Survival Studies," Biometrics, 42, 855-865.
22. Kimmel, M., and Flehinger, B. J. (1991), "Nonparametric Estimation of the Size-Metastasis Relationship in Solid Cancers," Biometrics, 47, 987-1004.
23. Klein, J. P., Klotz, J. H., and Grever, M. R. (1984), "A Biological Marker Model for Predicting Disease Transitions," Biometrics, 40, 927-936.
24. Lange, N., Carlin, B. P., and Gelfand, A. E. (1992), "Hierarchical Bayes Models for the Progression of HIV Infection Using Longitudinal CDA T-CeIl Numbers," Journal of the American Statistical Association, 87, 615-626.
25. Law, N. J., Taylor, J. M., and Sandler, H. (2002), "The Joint Modeling of a Longitudinal Disease Progression Marker and the Failure Time Process in the Presence of Cure," Biostatistics, 3, 547-563.
26. Loeve, F., Brown, M. L., Boer, R., van Ballegooijen, M., van Oortmarssen, G. J., and Habbema, J. D. (2000), "Endoscopic Colorectal Cancer Screening: A Cost-Saving Analysis," Journal of the National Cancer Institute, 92, 557-563.
27. Longini, I. M., Clark, W. S., Byers, R. H., Ward, J. W., Darrow, W. W., Lemp, G. F., and Hethcote, H. W. (1989), "Statistical Analysis of the Stages of HIV Infection Using a Markov Model," Statistics in Medicine, 8, 831-843.
28. Louis, T. A., Albert, A., and Heghinian, S. (1978), "Screening for Early Detection of Cancer III: Estimation of Disease Natural History," Mathematical Biosciences, 40, 111-144.
29. Luebeck, E. G., and Moolgavkar, S. H. (2002), "Multistage Carcinogenesis and the Incidence of Colorectal Cancer," Proceedings of the National Academy Science U.S.A., 99, 15095-15100.
30. Metropolis, N., Rosenbluth, A. W., Rosenbluth, M. N., Teller, A. H., and Teller, E. (1953), "Equations of State Calculations by Fast Computing Machine," Journal of Chemistry in Physics, 21, 1087-1091.
31. Moolgavkar, S. H., and Knudson, A. (1981), "Mutation and Cancer: A Model for Human Carcinogenesis," Journal of the National Cancer Institute, 66, 1037-1052.
32. Morrell, C. H., Pearson, J. D., Carter, H. B., and Brant, L. J. (1995), "Estimating Unknown Transition Times Using a Piecewise Nonlinear Mixed-Effects Model in Men With Prostate Cancer," Journal of the American Statistical Association, 90, 45-53.
33. Müller, P., and Quintana, F. A. (2004), "Nonparametric Bayesian Data Analysis," Statistical Science, 19, 95-110.
34. Parmigiani, G., Skates, S., and Zelen, M. (2002), "Modeling and Optimization in Early Detection Programs With a Single Exam," Biometrics, 58, 30-36.
35. Pawitan, Y., and Self, S. (1993), "Modeling Disease Marker Processes in AIDS," Journal of the American Statistical Association, 88, 719-726.
36. Pinsky, P. F. (2001), "Estimation and Prediction for Cancer Screening Models Using Deconvolution and Smoothing," Biometrics, 57, 389-395.
37. Plevritis, S. K., Salzman, P., Sigal, B. M., and Glynn, P. W. (2007), "A Natural History Model of Stage Progression Applied to Breast Cancer, Statistics in Medicine, 26, 581-595.
38. Raftery, A. L., and Lewis, S. (1992), "How Many Iterations in the Gibbs Sampler?" in Bayesian Statistics 4, eds. J. M. Bernardo, J. O. Berger, A. P. Dawid, and A. F. M. Smith, New York: Oxford University Press, pp. 763-773.
39. Shock, N. W., Greulich, R. C., Andres, R., Lakatta, E. G., Arenberg, D., and Tobin, J. D. (1984), "Normal Human Aging: The Baltimore Longitudinal Study of Aging," Publication 84-2450, National Institutes of Health Washington, DC.
40. Smith, B. J. (2005), "Bayesian Output Analysis Program (BOA) Version 1.1 User's Manual," available at http://www.public-health.uiowa.edu/ boa/.
41. Tanner, M. A. (1996), Tools for Statistical Inference (3rd ed.), New York: Springer-Verlag.
42. Taylor, J. M. G. (1989), "Models for the HIV Infection and AIDS Epidemic in the United States," Statistics in Medicine, 8, 45-58.
43. Walter, S. D., and Day, N. E. (1983), "Estimation of the Duration of a Preclinical Disease State Using Screening Data," American Journal of Epidemiology, 118, 865-886.
44. Whittemore, A. S., Lele, C., Friedman, G. D., Stamey, T., Vogelman, J. H., and Orentreich, N. (1995), "Prostate-Specific Antigen as Predictors of Prostate Cancer in Black Men and White Men," Journal of the National Cancer Institute, 87, 354-360.